Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients With Type 2 Diabetes Mellitus, Approaching NDA
HighTide Therapeutics Announces HTD1801 Meets the Primary Endpoints in Two Phase 3 Clinical Trials in Patients with Type 2 Diabetes Mellitus
HONG KONG - April 15, 2025 ( NEWMEDIAWIRE ) - HighTide Therapeutics, Inc. (2511.HK), a clinical-stage biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic liver and metabolic diseases, today announced that two Phase 3 trials (SYMPHONY 1 and SYMPHONY 2) of berberine ursodeoxycholate (HTD1801) in Chinese patients with type 2 diabetes mellitus (T2DM) met their primary endpoints and gated secondary endpoints.
The results of these two Phase 3 clinical trials provide robust evidence that HTD1801 delivers comprehensive benefits for patients with T2DM. Based on these highly positive read-outs, HighTide plans to submit a new drug application (NDA) for HTD1801 as a treatment for T2DM to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) later this year.
SYMPHONY 1 (NCT06350890) and SYMPHONY 2 (NCT06353347) are randomized, double-blind, placebo-controlled, Phase 3 clinical trials designed to evaluate the efficacy and safety of HTD1801 in adults with T2DM and inadequate glycemic control despite using diet and exercise (SYMPHONY 1; N=407) or Metformin (SYMPHONY 2; N=549). The primary endpoint in both studies was the change in HbA1c from baseline with HTD1801 compared to placebo after 24 weeks of treatment. Gated secondary endpoints included the percentage of subjects achieving HbA1c <7.0%, change in fasting plasma glucose (FPG), low-density lipoprotein cholesterol (LDL-C), glutamyl transpeptidase (GGT), and high-sensitivity C-reactive protein (hs-CRP).
The primary endpoint was achieved in both trials, showing a clinically meaningful, consistent glucose-lowering effect of HTD1801
SYMPHONY 1 (HTD1801 as monotherapy): At week 24, the reduction from baseline in HbA1c with HTD1801 (-1.3%) was superior to placebo. Further, those with more severe disease had a greater decrease with HTD1801: reduction in HbA1c was -1.5% for those with a baseline HbA1c ≥8.5%.
SYMPHONY 2 (HTD1801 as an add-on therapy to Metformin): At week 24, the reduction from baseline in HbA1c with HTD1801 (-1.2%) was superior to placebo. Further, those with more severe disease had a more significant decrease with HTD1801: reduction in HbA1c was -1.6% for those with a baseline HbA1c ≥8.5%.
In both Phase 3 trials, the efficacy on HbA1c reduction in patients treated with HTD1801 was sustained through week 24.
In both trials, gated secondary endpoints were achieved, suggesting multiple advantages of HTD1801 beyond glucose-lowering including improvement in cardiometabolic risk indicators
At week 24, in both studies, the proportion of patients who achieved HbA1c <7.0% was significantly higher in the HTD1801 treatment groups compared to placebo. Improvements in HbA1c with HTD1801 were parallelled with significant improvements in postprandial and fasting plasma glucose compared with placebo. In addition, HTD1801 demonstrated lipid-lowering effects, including significant reductions in low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). Moreover, HTD1801 treatment led to reductions in key inflammatory biomarkers - glutamyl transpeptidase (GGT) and high-sensitivity C-reactive protein (hs-CRP) - both of which are associated with cardiovascular risk in patients with T2DM.
Favorable safety and tolerability profile
Overall, safety and tolerability were favorable and consistent with previous clinical trials of HTD1801. The most commonly reported adverse events were gastrointestinal. In both studies <2% of patients discontinued early due to an adverse event. The incidence of hypoglycemia was low, with no severe hypoglycemia events reported.
'The encouraging results from these studies suggest that HTD1801 may offer a novel and improved therapeutic option for patients with T2DM,' said Dr. Linong Ji, the leading principal investigator for the two Phase 3 clinical trials and former Vice President of the International Diabetes Federation (IDF), Director of the Peking University Diabetes Center and Director of the Department of Endocrinology and Metabolism, Peking University People's Hospital. 'As an innovative drug candidate, HTD1801 exhibits a unique dual mechanism of action - AMP kinase activation and NLRP3 inflammasome inhibition - that is distinct from any existing T2DM drugs on the market. It is an oral therapy designed to deliver comprehensive clinical benefits - not only lowering blood glucose but also improving lipid metabolism and exerting anti-inflammatory effects - thereby potentially reducing diabetes-related complications and addressing significant unmet clinical needs. With continued clinical exploration, HTD1801 is expected to further expand its application to benefit patients globally. In today's pharmaceutical landscape, investment has become heavily concentrated on GLP-1-based drug development. While GLP-1 therapies hold significant clinical value, they do not adequately address the full spectrum of pathophysiological mechanisms underlying T2DM. To truly meet the multifaceted needs of T2DM management, continued innovation across a diverse range of therapeutic targets remains essential.'
'We extend our deepest gratitude to the patients who participated in these pivotal trials,' said Dr. Liping Liu, HighTide's founder and CEO. 'HTD1801's innovative dual-action approach – targeting both metabolic regulation and inhibiting inflammation – represents a potential breakthrough in diabetes treatment. We look forward to sharing data from the 28-week open-label extension of these studies and a Phase 3 head-to-head comparison with the dapagliflozin; we will continue to explore the clinical potential of HTD1801 to provide patients with chronic metabolic diseases a comprehensive treatment solution.'
About Type 2 Diabetes Mellitus (T2DM)
According to the International Diabetes Federation (IDF), 537 million adults (ages 20-79) were living with diabetes in 2021, and this number is projected to grow to 783 million (representing 1 in 8 adults) by 2045, of these, around 90% are T2DM cases. China has the largest population of diabetes patients worldwide, estimated to be 141 million in 2021, and projected to grow to 174 million in 2045. Diabetes is a global societal burden leading to over 6 million deaths per year. To address this urgent challenge, there is a critical need for innovative therapies that can deliver comprehensive clinical benefits for patients worldwide.
About Berberine Ursodeoxycholate (HTD1801)
Berberine ursodeoxycholate (HTD1801) is an orally delivered, gut-liver anti-inflammatory metabolic modulator being developed for the treatment of metabolic and digestive diseases. HTD1801, an ionic salt of berberine and ursodeoxycholate, is a new molecular entity with a unique dual mechanism of action: AMP kinase activation and NLRP3 inflammasome inhibition. These two key mechanistic pathways have been associated with improvements in insulin resistance, glucose metabolism, lipid metabolism, and hepatic inflammation, potentially providing a comprehensive treatment platform for the multifaceted nature of complex metabolic diseases.
HTD1801 is being developed for multiple indications. In addition to T2DM, its efficacy in treating metabolic dysfunction-associated steatohepatitis (MASH) has been demonstrated in a Phase 2a clinical trial and a global multicenter Phase 2b trial assessing the histologic benefit of HTD1801 is currently ongoing, with topline results expected in 2025.
About HighTide Therapeutics
HighTide Therapeutics, Inc. (Stock Code: 2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional, multi-targeted therapies with poly-indication potential across chronic liver and metabolic diseases with significant unmet medical needs. HighTide is currently developing several clinical assets and associated global intellectual property rights, and advancing multiple mid-to-late-stage clinical trials including therapies for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes mellitus (T2DM), severe hypertriglyceridemia (SHTG) and primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), HighTide's lead drug candidate, received Fast Track designation from the United States Food and Drug Administration for both MASH and PSC and Orphan Drug designation for PSC. HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project in China.
For more information, please visit www.hightidetx.com.
Contact: [email protected]
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
4 hours ago
- Los Angeles Times
Early-Stage Technology Disruptions and Trends Set to Define the Future of Business Systems
Researchers point to technologies addressing GenAI-enabled code architecture, disinformation security and surface asset management as the most likely to be widely adopted by businesses by 2030, while leaders find themselves reassessing cloud usage and not overlooking the ever-growing need for effective cybersecurity solutions Through its research and surveys of C-suiters, Gartner, Inc. has identified the most likely emerging technology disruptions that will impact businesses and define the future of business systems. Technology leaders are clearly prioritizing these over the next five years, as they present competitive opportunities in the near term and will eventually grow to become standard throughout businesses. 'Technology leaders must take action now to gain a first-mover advantage with these technologies,' said Bill Ray, distinguished VP analyst at Gartner. 'Innovative advancements like generative AI-enabled code architecture, disinformation security and Earth intelligence will provide the differentiation needed to help enterprises pull ahead of the pack in terms of data and product offerings.' Each disruptor is significant in its own right, but in combination, they start to define broader emerging solutions to new business practices. For example, advancing GenAI technologies will spawn new solutions around Earth intelligence and business simulation, spur the expansive growth of domainspecific language models and lead to higher functioning tools. GenAI solutions systems using free-form text and multimedia inputs/outputs will displace the conventional form-oriented sequential UI in established enterprise applications and enable new user scenarios. 'To remain competitive, traditional enterprise application software vendors will need to refactor applications to serve composable GenAI solutions that are invoked on demand via textual and multimodal prompts,' said Ray Valdes, VP analyst at Gartner. Because of this, Gartner predicts that by 2029, more than 50% of user interactions linked to enterprise business processes will leverage large language models to bypass the UI layer in traditional enterprise applications, up from less than 5% today. Disinformation security is an emerging discipline focused on threats from outside the corporate-controlled network. It includes a suite of technologies, such as deepfake detection, impersonation prevention and reputation protection, which can address disinformation to help enterprises discern trust, protect their brand and secure their online presence. Gartner predicts that by 2030, at least half of enterprises will have adopted products or services to address disinformation security, up from less than 5% in 2024. 'Disinformation attacks use external infrastructure, like social media, and originate from areas with limited legal oversight,' said Alfredo Ramirez IV, senior director analyst at Gartner. 'Tech leaders must add 'disinformation-proofing' to products by using AI/machine learning for content verification and data provenance tracking to help users discern the truth.' Gartner predicts that by 2028, 80% of major Earth surface assets globally will be monitored by active satellites. Earth intelligence tech uses AI to analyze satellite, aerial and ground data to monitor Earth's assets and activities, providing insights for decision-making. 'That doesn't mean maps and charts. Earth intelligence is delivering numbers on global nickel production, theme park revenue and the health of wheat crops, to name just a few,' said Ray. Given the breadth of applications, Earth intelligence is applicable to all industries and enterprises. Defense has been the first adopter, but improvements in the quality of data and analysis techniques have rapidly expanded the use cases. The Earth intelligence market is now divided between those who capture the data, those who interpret and analyze it and those who generate industry-specific insights. 'Earth intelligence applies to every business,' said Ray. 'Enterprises can gain an early advantage by creatively and strategically applying Earth intelligence to significantly enhance specific functionalities of existing systems or to compete via new net capabilities.' In a separate research report, Gartner has also announced the top trends shaping the future of cloud adoption over the next four years. These include cloud dissatisfaction, AI/machine learning (ML), multicloud, sustainability, digital sovereignty and industry solutions. Joe Rogus, director, advisory at Gartner, said, 'These trends are accelerating the shift in how cloud is transforming from a technology enabler to a business disruptor and necessity for most organizations. Over the next few years, cloud will continue to unlock new business models, competitive advantages and ways of achieving business missions.' Cloud adoption continues to grow, but not all implementations succeed. Gartner predicts 25% of organizations will have experienced significant dissatisfaction with their cloud adoption by 2028, due to unrealistic expectations, suboptimal implementation and/or uncontrolled costs. To remain competitive, enterprises need a clear cloud strategy and effective execution. Gartner research indicates that those who have successfully addressed upfront strategic focus by 2029 will find their cloud dissatisfaction will decrease. Gartner also predicts 50% of cloud computing resources will be devoted to AI workloads by 2029, up from less than 10% today. 'This all points to a fivefold increase in AI-related cloud workloads by 2029,' said Rogus. 'Now is the time for organizations to assess whether their data centers and cloud strategies are ready to handle this surge in AI and ML demand. In many cases, they might need to bring AI to where the data is to support this growth.' Many organizations that have adopted multicloud architecture find connecting to and between providers a challenge. This lack of interoperability between environments can slow cloud adoption, with Gartner predicting more than 50% of organizations will not get the expected results from their multicloud implementations by 2029. Gartner recommends identifying specific use cases and planning for distributed apps and data in the organization that could benefit from a cross-cloud deployment model. This enables workloads to operate collaboratively across different cloud platforms, as well as different onpremises and colocation facilities. AI adoption, tightening privacy regulations and geopolitical tensions are also driving demand for sovereign cloud services. Organizations will be increasingly required to protect data, infrastructure and critical workloads from control by external jurisdictions and foreign government access. Gartner predicts over 50% of multinational organizations will have digital sovereign strategies by 2029, up from less than 10% today. 'As organizations proactively align their cloud strategies to address digital sovereignty requirements, there are already a wide range of offerings that will support them,' said Rogus. 'However, it's important they understand exactly what their requirements are, so they can select the right mix of solutions to safeguard their data and operational integrity.' With all the talk of businesses onboarding GenAI and other emerging technology solutions, it's easy to overlook cybersecurity tools. CEOs, however, are not forgetting to lock the proverbial door. Gartner's research has shown that a whopping 85% of CEOs surveyed say that cybersecurity is critical for business growth moving forward. In a survey of 456 CEOs and other senior business executives, 61% of CEOs are concerned about cybersecurity threats, driven in large part by AI's growing role in commercial activity and the political debates about the sourcing and use of advanced technologies. As risk thresholds shift, they view cybersecurity as a key driver. 'Cybersecurity is no longer just about protection; it's a critical driver for business growth,' said David Furlonger, distinguished vice president analyst and Gartner fellow. 'With 85% of CEOs recognizing its importance, security leaders have a unique opportunity to demonstrate the value of cybersecurity investments not only in safeguarding assets but also in enabling strategic business objectives.' 'Effective communication is key,' said Furlonger. 'CEOs should highlight the role of security leaders in both protecting the business and enhancing cybersecurity to drive growth. This involves, for example, assessing risks in foreign markets and intellectual property protection. Security leaders are positioned to significantly influence value generation, and they should communicate how cybersecurity aids enterprise growth.' With regulatory changes and cybersecurity threats challenging competitiveness, CEOs said they see a direct linkage between cybersecurity capabilities and enterprise growth. Meanwhile, C-suiters' comfort level with AI is far from established at this point. Only 44% of CIOs are deemed by their CEOs to be 'AI-savvy' according to the Gartner data. The survey revealed that 77% of CEOs believe that AI is indeed ushering in a new business era, yet they feel their organization's leading technology experts lack the knowledge and capabilities to support, drive or accelerate business outcomes in this evolving landscape. 'We have never seen such a disproportionate gap in CEOs' impressions about technological disruption,' said Furlonger. 'AI is not just an incremental change from digital business. AI is a step change in how business and society work. A significant implication is that if savviness across the C-suite is not rapidly improved, competitiveness will suffer and corporate survival will be at stake.' CEOs perceive even the CIO, chief information security officer (CISO) and chief data officer (CDO) as lacking AI savviness. CEOs highlighted that the top two limiting factors impacting AI's deployment and use are the inability to hire adequate numbers of skilled people and an inability to calculate value or outcomes. 'CEOs have shifted their view of AI from just a tool to a transformative way of working,' said Jennifer Carter, principal analyst at Gartner. 'This change has highlighted the importance of upskilling. As leaders recognize AI's potential and its impact on their organizations, they understand that success isn't just about hiring new talent. Instead, it's about equipping their current employees with the skills needed to seamlessly incorporate AI into everyday tasks.'
Business Upturn
16 hours ago
- Business Upturn
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, June 21, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the 'Class Period'), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc. , No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Tempus AI class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence, including generative AI. The Tempus AI class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Tempus AI inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (ii) the credibility and substance of Tempus AI's joint venture with SoftBank Group Corporation was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus AI; (iii) Tempus AI-acquired Ambry Genetics Corporation had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (iv) AstraZeneca PLC had reduced its financial commitments to Tempus AI through a questionable 'pass-through payment' via a joint agreement between it, Tempus AI, and Pathos AI, Inc.; and (v) the above issues revealed weakness in core operations and revenue prospects. The Tempus AI class action lawsuit further alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued research report on Tempus AI that raised numerous red flags over Tempus AI's management, operations, and financial reporting. On this news, the price of Tempus AI stock fell more than 19%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Tempus AI common stock during the Class Period to seek appointment as lead plaintiff in the Tempus AI class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Tempus AI class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Tempus AI class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Tempus AI class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
New York Post
a day ago
- New York Post
Dog's ashes among dozens to rocket into orbit this weekend
Bone voyage! A beloved dog named Franz will take his final leap this weekend — into Earth's orbit. The yellow labrador's ashes will be on board the inaugural Perseverance Flight from Texas-based Celestis Inc., which is scheduled to launch around 5:30 p.m. Sunday from Vandenberg Space Force Base in Santa Barbara, CA. 4 Franz was like a sibling to Elizabeth Moore before he died at age 13 in October 2020. Celestis, Inc Carrying a total of 166 titanium and aluminum capsules, each about a quarter to a half-inch in size and filled with DNA or cremated remains, the 23-foot-tall SpaceX Falcon 9 rocket will take two trips around Earth's low orbit at a mind-boggling 17,000 mph. The space flight will last about three hours before the rocket — still carrying its priceless payload — re-enters the atmosphere and lands in the Pacific Ocean somewhere between Alaska and Hawaii, according to Celestis CEO and co-founder Charles Chafer. A recovery ship, which was already out at sea Friday in anticipation of the launch, 'will track the incoming rocket, hopefully get a visual on it, and then go pick it up out of the ocean,' Chafer explained. 4 The Texas-based company Celestis Inc.'s inaugural Perseverance Flight will take two trips around Earth's Lower Orbit after blastoff on Sunday. The capsules will first be transported to Germany, then, within two months, distributed back to the families, who each paid a whopping $3,500 to send their loved one to the stars. While the price to send Franz on the voyage was 'a lot more' than the pooch itself, his owner, Harvin Moore, said with a laugh, it was only fitting for the 'space-fanatic' Moore family to send the pup beyond the stratosphere. 'He was the best dog, just so soft and nice and loved hugs,' recalled Moore, 60, who lives in Dripping Springs, Texas, just outside Austin. 4 The Moore family can't wait to watch their beloved pooch go galactic. Celestis, Inc Franz, who was 13 when he died in October 2020, was more like a sibling than a pet to Moore's now 26-year-old daughter, Elizabeth, and son, Quinn, 21, he said. Now, the family can't wait to watch the good boy go galactic. 'The emotional power of being with a group of people who are celebrating the life of a loved one in this way … it's amazing. It's nothing we'll ever forget,' said Moore. 'It's just pure joy.' 4 The Perseverance Flight will carry a total of 166 titanium and aluminum capsules, ranging in size from a quarter to a half-inch, filled with DNA or cremated remains. Celestis, Inc 'Many people whose ashes and DNA are flying are people that always wanted to go to space in their lifetime but were never able to do that. It also helps families move from feelings of grief to joy,' Chafer said. The cremated remains of Wesley Dreyer — an aerospace engineer who helped investigate the cause of the Space Shuttle Challenger's shocking explosion after takeoff on Jan. 28, 1986 — will also be on board the Perseverance Flight, as well as DNA from a living, 3-year-old German boy.
